

WATCHMAN™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE

Stroke Prevention Treatment for Patients with Atrial Fibrillation
Who Are Unable to Take Anticoagulation

Kettering Health Network is now providing a procedure that reduces the risk of stroke in patients with non-valvular atrial fibrillation. This procedure eliminates the need for long-term use of anticoagulants.

Indications for Use

The Watchman device is indicated to reduce the risk of stroke from the LAA in patients with non-valvular atrial fibrillation who:

- Are at increased risk of stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy.
- Are deemed to be suitable for anticoagulants.
- Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulants such as GI bleeding, severe bruising, or excessive bleeding.


About the Procedure

- Typically performed under general anesthesia in a cath lab using a standard transseptal technique.
- Procedure usually lasts about an hour and the patient is discharged the next day.
- Patients remain on short-term warfarin post procedure for 45 days until the device endothelializes.

Benefits

- Demonstrates comparable stroke risk reduction compared to warfarin.
- Demonstrates reduction in cardiovascular death by 56% compared to warfarin.
- 92% of patients stopped warfarin after 45 days.
- 99% of patients stopped warfarin at one year.


For more information or to refer a patient call **(937) 395-6023**



Kettering Health Network Watchman™ Team



Raja Nazir, MD
Interventional
Cardiologist



K. Shahid Baig, MD
Cardiac
Electrophysiologist



Brian Schwartz, MD
Interventional/Structural
Heart Cardiologist



ketteringhealth.org/heartcare

**Benjamin and Marian Schuster
Heart Hospital**

3535 Southern Boulevard
Kettering, Ohio 45429
(937) 395-6023